Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lee’s Pharmaceutical Holdings Limited ( (HK:0950) ) has shared an announcement.
Lee’s Pharmaceutical Holdings has scheduled a board meeting on 30 March 2026 at its Hong Kong Science Park offices to review and approve the annual results for the year ended 31 December 2025. The board will also consider whether to recommend a final dividend, signaling an upcoming update on the company’s financial performance and potential shareholder returns.
The announcement, made under Hong Kong listing rules, primarily serves to formally notify investors of the timing of the results release and dividend deliberation. It underscores routine corporate governance procedures that may influence market expectations around the company’s earnings, capital allocation and overall financial health when the full-year figures are later disclosed.
The most recent analyst rating on (HK:0950) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Lee’s Pharmaceutical Holdings Limited stock, see the HK:0950 Stock Forecast page.
More about Lee’s Pharmaceutical Holdings Limited
Lee’s Pharmaceutical Holdings Limited is a Hong Kong–listed pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical products. The group operates through various subsidiaries and is overseen by a board comprising executive, non-executive and independent non-executive directors, reflecting a conventional governance structure for a listed drug maker.
Average Trading Volume: 798,873
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$806.7M
For a thorough assessment of 0950 stock, go to TipRanks’ Stock Analysis page.